Table 3.
The higher expression of one or multiple immune checkpoint genes of the 31-gene set was associated with prolonged overall survival in each of the 25 TCGA cancer types.
| TCGA cancer type | Abbreviation | Immune coinhibitory/costimulatory genes whose lower expression associated with shorter overall survival |
|---|---|---|
| Adrenocortical carcinoma | ACC | CD40, CD274 (PD-L1), LRIG1 |
| Bladder urothelial carcinoma | BLCA | CEACAM1, TNFRSF18 |
| Breast invasive carcinoma | BRCA | TNFRSF18, CD40LG, CLEC4G, TNFRSF4, C10orf54 (VISTA), CTLA4 |
| Cervical and endocervical cancers | CESC | CD27, LGALS9 |
| Colorectal adenocarcinoma | COADREAD | TIGIT, CTLA4, ICOS, LGALS9, PDCD1 (PD-1) |
| Glioblastoma multiforme | GBM | TNFSF18 |
| Glioma | GBMLGG | LRIG1 |
| Head and neck squamous cell carcinoma | HNSC | TNFRSF18, CD27, CTLA4, TNFRSF4 |
| Kidney chromophobe | KICH | PVRL2 (NECTIN2) |
| Kidney renal clear cell carcinoma | KIRC | CD274 (PD-L1), CEACAM1, LRIG3 |
| Brain lower grade glioma | LGG | LRIG1 |
| Liver hepatocellular carcinoma | LIHC | CD27, PDCD1LG2 (PD-L2) |
| Lung adenocarcinoma | LUAD | ICOSLG, LRIG1, LRIG2, LRIG3 |
| Lung squamous cell carcinoma | LUSC | TNFRSF18 |
| Mesothelioma | MESO | C10orf54 (VISTA) |
| Ovarian serous cystadenocarcinoma | OV | CD40 |
| Pancreatic adenocarcinoma | PAAD | TNFRSF4 |
| Rectum adenocarcinoma | READ | ICOS, PDCD1 (PD-1), PDCD1LG2 (PD-L2), TNFRSF9 |
| Sarcoma | SARC | TNFRSF4, CD40, CD40LG, LGALS9, C10orf54 (VISTA) |
| Skin Cutaneous Melanoma | SKCM | CD27, TNFRSF18 |
| Stomach adenocarcinoma | STAD | TIGIT, LGALS9, PDCD1 (PD-1), C10orf54 (VISTA) |
| Stomach and Esophageal carcinoma | STES | TNFSF4, CD40, CD70, PDCD1LG2 (PD-L2), TNFRSF18 |
| Thymoma | THYM | ICOS |
| Uterine Carcinosarcoma | UCS | ICOS |
| Uveal Melanoma | UVM | CD40, PDCD1LG2 (PD-L2) |